Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HK1 | P19367 | 1/20 | 0.36 |
| ▸ | HK2 | P52789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767213 | 1.00 | PYGB (0.45) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL19757480 | 0.88 | PYGB (0.48) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL19757478 | 0.88 | PYGB (0.48) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL23315803 | 0.88 | PYGB (0.48) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL23651957 | 0.88 | PYGB (0.48) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL18391238 | 0.87 | PYGB (0.47) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL24468938 | 0.86 | PYGB (0.62) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL18365283 | 0.86 | PYGB (0.62) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL18390833 | 0.84 | PYGB (0.45) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL16664876 | 0.84 | LMNA (0.55) | PYGBGAAKDM4ELMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | PTMS, DNPEP, STT3A | PYGB 782/4885GAA 735/4885KDM4E 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.